CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


MethotrexateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug2868 leucovorin Wiki 0.50
drug2672 Voraxaze Wiki 0.50
drug2104 Rituximab Wiki 0.50
drug566 Chloroquine or Hydroxychloroquine Wiki 0.29
drug1822 Placebo Wiki 0.03

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D008223 Lymphoma, NIH 0.25
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002665 Lymphoma HPO 0.25

There are 4 clinical trials

Clinical Trials


1 LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.

NCT03684980 Central Nervous System Lymphoma Drug: Voraxaze Drug: Methotrexate Drug: Rituximab Drug: leucovorin
MeSH:Lymphoma
HPO:Lymphoma

Primary Outcomes

Description: All serum samples will be tested via MTX immunoassay (measures MTX levels in addition to byproducts) as well as HPLC or mass spectroscopy which will reveal plasma concentrations of MTX and DAMPA separately.

Measure: number of patients that have significant reduction of serum methotrexate levels

Time: 1 year

2 Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles: A Phase I/II Study

The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.

NCT04352465 COVID-19 Drug: Methotrexate Drug: Methotrexate Drug: Methotrexate

Primary Outcomes

Description: Clinical condition will be measured by lung injuries

Measure: Change in clinical conditions

Time: 21 days

Secondary Outcomes

Description: Evaluation of Pneumonia change

Measure: Change of Clinical symptoms - respiratory rate

Time: 21 days

Description: oxygen saturation

Measure: Hypoxia

Time: 21 days

Description: PaO2 / FiO2 ratio

Measure: Changes of blood oxygen

Time: 21 days

Description: C-reactive protein and ferritin

Measure: Inflammatory parameters

Time: 21 days

Description: Time to wean off oxygen invasive ventilatory support

Measure: Evolution of Acute Respiratory Syndrome

Time: 21 days

Description: Time to be discharged from hospital

Measure: Hospital discharge

Time: 21 dyas

Description: Time to be discharged from ICU

Measure: ICU discharge

Time: 21 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Rate of mortality

Time: 4 months

3 Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles: A Phase I/II Study

The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.

NCT04352465 COVID-19 Drug: Methotrexate Drug: Methotrexate Drug: Methotrexate

Primary Outcomes

Description: Clinical condition will be measured by lung injuries

Measure: Change in clinical conditions

Time: 21 days

Secondary Outcomes

Description: Evaluation of Pneumonia change

Measure: Change of Clinical symptoms - respiratory rate

Time: 21 days

Description: oxygen saturation

Measure: Hypoxia

Time: 21 days

Description: PaO2 / FiO2 ratio

Measure: Changes of blood oxygen

Time: 21 days

Description: C-reactive protein and ferritin

Measure: Inflammatory parameters

Time: 21 days

Description: Time to wean off oxygen invasive ventilatory support

Measure: Evolution of Acute Respiratory Syndrome

Time: 21 days

Description: Time to be discharged from hospital

Measure: Hospital discharge

Time: 21 dyas

Description: Time to be discharged from ICU

Measure: ICU discharge

Time: 21 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Rate of mortality

Time: 4 months

4 Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles: A Phase I/II Study

The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.

NCT04352465 COVID-19 Drug: Methotrexate Drug: Methotrexate Drug: Methotrexate

Primary Outcomes

Description: Clinical condition will be measured by lung injuries

Measure: Change in clinical conditions

Time: 21 days

Secondary Outcomes

Description: Evaluation of Pneumonia change

Measure: Change of Clinical symptoms - respiratory rate

Time: 21 days

Description: oxygen saturation

Measure: Hypoxia

Time: 21 days

Description: PaO2 / FiO2 ratio

Measure: Changes of blood oxygen

Time: 21 days

Description: C-reactive protein and ferritin

Measure: Inflammatory parameters

Time: 21 days

Description: Time to wean off oxygen invasive ventilatory support

Measure: Evolution of Acute Respiratory Syndrome

Time: 21 days

Description: Time to be discharged from hospital

Measure: Hospital discharge

Time: 21 dyas

Description: Time to be discharged from ICU

Measure: ICU discharge

Time: 21 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Rate of mortality

Time: 4 months


Related HPO nodes (Using clinical trials)